Handroanthus avellanedae (Lorentz ex Griseb.) Mattos; Tabebuia avellanedae Lorentz ex Griseb.; T. impetiginosa (Mart ex DC.) Standl.; and others Bignoniaceae Ipê roxo; pau d’arco; red or purple lapacho; taheebo Tabebuiae cortex Bark (inner bark preferred) Naphthoquinones, the most important being lapachol and β-lapachone, iridoid, lignan, isocoumarin, phenolic and phenylethanoid glycosides (Gómez-Castellanosa et al. 2009). Several novel benzoyl apiosides have been isolated (Suo et al. 2012). The clinical evidence is limited to studies on the potential anticancer effects in phase I and II clinical trials (see Gómez-Castellanosa et al. 2009). In the 1960s, an Investigational New Drug Application (IND) was filed in the United States, and phase I clinical trials were initiated, with doses up to 4000 mg/day administered orally. No therapeutic response was observed, and it was determined that satisfactory blood levels could not be obtained by oral administration; also, some toxicity was observed. The IND was closed in 1970 (Gómez-Castellanosa et al. 2009).
Lapacho
Handroanthus impetiginosus (Mart. ex DC.) Mattos
Synonyms:
Family:
Other common names:
Drug name:
Botanical drug used:
Main chemical compounds:
Clinical evidence:
Anticancer effects:
Pre-clinical evidence and mechanisms of action:
Anticancer effects:
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
